Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 2/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.54 |
| ▸ | LOXL2 | Q9Y4K0 | 5/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.44 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.41 |
| ▸ | ABAT | P80404 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28135249 | 0.98 | ADRB2 (0.96) | ADRB2HRH3TAAR1LOXL2CYP2A6 | |
| SCHEMBL13978024 | 0.88 | ADRB2 (0.78) | ADRB2HRH3TAAR1LOXL2CYP2A6 | |
| SCHEMBL23291109 | 0.83 | ADRB2 (0.70) | ADRB2TAAR1LOXL2CYP2A6 | |
| SCHEMBL29676764 | 0.81 | ADRB2 (0.68) | ADRB2TAAR1LOXL2CYP2A6CLK4 | |
| SCHEMBL112429 | 0.81 | ADRB2 (0.68) | ADRB2TAAR1LOXL2CYP2A6CLK4 | |
| SCHEMBL27278090 | 0.80 | ADRB2 (0.67) | ADRB2HRH3TAAR1LOXL2CYP2A6 | |
| SCHEMBL6685962 | 0.80 | CLK4 (0.64) | ADRB2CYP2A6CLK4AOC3 | |
| SCHEMBL16269874 | 0.79 | ADRB2 (0.66) | ADRB2HRH3TAAR1LOXL2CYP2A6 | |
| SCHEMBL18814009 | 0.79 | ADRB2 (0.65) | ADRB2HRH3TAAR1LOXL2CYP2A6 | |
| SCHEMBL31565171 | 0.78 | ADRB2 (0.62) | ADRB2HRH3TAAR1LOXL2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102271682-A | P2x3, receptor antagonists for treatment of pain | — | 2011-12-07 | — | — | CN | claimed |
| EP-4618974-A1 | OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20240383900-A1 | SUBSTITUTED PYRAZOLO [1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2024-11-21 | — | — | US | disclosed |
| WO-2024107615-A1 | OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-05-23 | — | — | WO | disclosed |
| CN-117940427-A | Substituted pyrazolo [1,5-a ] pyrimidine-7-amine compounds as CDK inhibitors and therapeutic uses thereof | 卡里克治疗有限公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4355426-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2024-04-24 | — | — | EP | disclosed |
| WO-2022263604-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2022-12-22 | — | — | WO | disclosed |
| CN-105461699-B | Substituted heterocyclic compound and its application method and purposes | 广东东阳光药业有限公司 | 2019-07-09 | — | — | CN | disclosed |
| US-20180071232-A1 | COMPOSITIONS AND METHODS FOR TREATING RESPIRATORY INJURY OR DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-03-15 | — | — | US | disclosed |
| US-9849098-B2 | Compositions and methods for treating respiratory injury or disease | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-12-26 | — | — | US | disclosed |
| CN-101585814-B | Aryl pyrimidine ortho-single halogen substituted compound and synthetic method thereof | UNIV SHANGHAI SCIENCE & TECH | 2011-08-10 | — | — | CN | disclosed |
| CN-101812022-A | Ortho-monovinylphenyl substituted compound of aryl pyrimidine and synthesizing method thereof | UNIV SHANGHAI | 2010-08-25 | — | — | CN | disclosed |
| CN-101654439-A | Ortho-position dihalogen substitution compound of aryl pyrimidine and preparing method thereof | UNIV SHANGHAI | 2010-02-24 | — | — | CN | disclosed |
| US-20100029669-A1 | 3-(SUBSTITUTED ETHYL)-RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS | JANSSEN PHARMACEUTICA, NV (BE) | 2010-02-04 | — | — | US | disclosed |
| CN-101585814-A | Aryl pyrimidine ortho-single halogen substituted compound and synthetic method thereof | UNIV SHANGHAI SCIENCE & TECH (CN) | 2009-11-25 | — | — | CN | disclosed |
| CN-101406469-A | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | LUNDBECK & CO AS H (DK) | 2009-04-15 | — | — | CN | disclosed |
| CN-100446767-C | Use of GAL3 receptor antagonists for the manufacture of a medicament for the treatment of depression and/or anxiety and compounds useful in such a method | SYNAPTIC PHARMA CORP (DK) | 2008-12-31 | — | — | CN | disclosed |
| CN-1214014-C | HIV inhibiting pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2005-08-10 | — | — | CN | disclosed |
| CN-1499970-A | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | �����յٿ�ҩ������˾ | 2004-05-26 | — | — | CN | disclosed |
| CN-1295564-A | HIV inhibiting pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2001-05-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071232-A1 | COMPOSITIONS AND METHODS FOR TREATING RESPIRATORY INJURY OR DISEASE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C9, C1S | ADRB2 1942/4885HRH3 1229/4885TAAR1 4081/4885 |
| US-20240383900-A1 | SUBSTITUTED PYRAZOLO [1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | CDK3, CDK1, CDK2 | ADRB2 3560/4885HRH3 2199/4885TAAR1 3817/4885 |
| US-20100029669-A1 | 3-(SUBSTITUTED ETHYL)-RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS | RIF1, RPS27, MRPL21 | ADRB2 2992/4885HRH3 4213/4885TAAR1 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.